Cellectar Biosciences, Inc. — Q1 2017 Form 10-Q
Business context and reporting period. The clinical-stage biopharmaceutical company develops phospholipid drug conjugates (PDCs) for cancer treatment and imaging. This unaudited report covers the three months ended March 31, 2017, compared with Q1 2016. Its lead candidate, CLR 131, was in Phase 1 and Phase 2 studies; the company reported advancing its Phase 1 multiple myeloma study to Cohort 4 and initiating a Phase 2 study in March 2017. The company reported no product revenues.
Financial results and liquidity
| Metric | Q1 2017 | Q1 2016 / prior balance-sheet date |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $1.86 million | $1.04 million |
| General and administrative expense | $0.96 million | $0.96 million |
| Operating loss | $2.81 million | $2.00 million |
| Net loss (income) | $2.89 million loss | $0.82 million income |
| Operating cash used | $2.99 million | $1.82 million |
| Cash and cash equivalents | $11.24 million at March 31, 2017 | $11.44 million at December 31, 2016 |
| Total assets / total liabilities | $15.30 million / $1.55 million | $15.32 million / $1.78 million |
R&D expense increased approximately 79%, principally reflecting higher clinical research, contract manufacturing and supply, and consulting costs associated with the hematologic malignancies Phase 2 program. G&A was essentially unchanged. The prior-year net income reflected a $2.82 million gain on derivative-warrant revaluation; Q1 2017 instead recorded an $82,000 loss, so the net-result comparison does not reflect operating performance alone. No profit margin is meaningful because the company had no reported revenue.
Cash used in investing activities was $66,000, primarily fixed-asset purchases. Financing provided $2.85 million, including $2.93 million from exercise of Series C warrants, partly offset by $87,000 of note repayments. The Wisconsin Economic Development Corporation loans were paid in full; no notes payable remained at quarter-end. Capital lease obligations totaled approximately $7,000. Current assets were $12.19 million and current liabilities $1.40 million at March 31.
Material changes, outlook, and risks
- Management said the March 31 cash balance was expected to fund operations at budgeted levels into the second quarter of 2018. Beyond then, execution of the operating plan depends on additional financing, a strategic transaction, or other funding; the company said it had not entered negotiations for financing and gave no assurance of obtaining it.
- The filing states that continued losses and the need for additional financing raise substantial doubt about the company’s ability to continue as a going concern within one year of issuance. Management expects operating losses to continue for the foreseeable future.
- CLR 131’s Phase 1 Data Monitoring Committee supported escalation to Cohort 4 after favorable Cohort 3 safety review. A $2 million NCI SBIR grant supports development, including the Phase 2 study. These are development updates, not evidence of regulatory approval or commercial revenue.
- Warrant exercises brought in cash but increased common shares outstanding; 8.76 million warrants and 508,733 options remained outstanding at quarter-end. Potential future exercises, new financings, or partnerships could dilute shareholders or require sharing economic or proprietary rights.
- The company cited clinical and preclinical development, regulatory, manufacturing, competition, and financing risks. It reported no legal proceedings expected to materially affect the financial statements and said disclosure controls were effective, with no significant change in internal control over financial reporting.
Important facts for investors to verify
- Whether spending and clinical-trial progress remain consistent with the stated cash runway, and what financing is needed to operate beyond Q2 2018.
- CLR 131 trial enrollment, safety, efficacy data, timelines, and the scope and funding terms of the Phase 2 program.
- The composition and assumptions behind derivative-warrant revaluation, and the potential dilution from outstanding warrants, options, and future capital raises.
- Whether the going-concern uncertainty changes in subsequent filings; the stated runway does not eliminate the filing’s substantial-doubt disclosure.